Velsera Announces New Capabilities with Latest Nextflow Release

Cutting Costs, Boosting Speed: Transformative Optimizations Now Available on the Seven Bridges Platform for Researchers Everywhere 

Boston, MA – [November 7, 2024] – Velsera, a leading global healthcare technology company, today announces transformative enhancements to Nextflow pipeline performance on the Seven Bridges Platform, unveiled during the Nextflow Summit on October 31, 2024, in Barcelona. These optimizations enable end users—researchers, bioinformaticians, and data scientists—to process data faster, cut cloud costs, and tackle large-scale analysis with ease and precision. 

Velsera’s implementation of Nextflow provides optimized nf-core/rnaseq pipelines, achieving up to 66% cloud cost savings compared to AWS Batch with significant reductions in execution time for scalable data analysis. Leveraging advanced features such as multi-instance execution, process instance hints, memorization (reuse), and elastic disk, users can accelerate data processing timelines, improve efficiency, and gain insights faster, all while maintaining pipeline portability.  

“These performance improvements enable researchers to achieve results faster and at a lower cost, making it possible to stretch limited budgets further,” said Jack DiGiovanna, Chief Science Officer at Velsera. “More importantly, the enhancements allow researchers on the Velsera Seven Bridges Platform to seamlessly leverage the nf-core analysis tools which are built and maintained by a thriving, international bioinformatics community.” 

Empowering Research with Advanced Nextflow Capabilities 

Velsera’s optimization on a 78-sample liver biopsy dataset showcased the power of these enhancements. By tapping into the Seven Bridges Platform’s advanced performance and cost optimization features, the Velsera team achieved notable reductions in CPU hours and wall-clock time, delivering actionable results more quickly and cost-effectively than previously possible. 

For research teams, this means: 

• Faster Insights: Reduced processing times allow users to move from data to discovery more quickly, accelerating the pace of research. 

• Significant Cost Savings: Optimize cloud resource use with features such as multi-instance execution, memorization, elastic disk, and spot instance support, directly translating to lower operational costs. 

• Enhanced Efficiency Through Expert-Led Optimization: The Velsera Bioinformatics  team has carefully refined these enhancements to maximize the impact on both cost and speed. With their expertise, users can take full advantage of these features, seamlessly scaling their analyses while maintaining reproducibility, portability, and efficient resource use across diverse cloud environments. This empowers teams to perform complex, large-scale research at a fraction of the cost and time.  

Achieve More with the Seven Bridges Platform 

Velsera invites teams to explore the Seven Bridges Platform for their Nextflow and CWL workflows, now optimized for unparalleled performance and cost savings. Their full study, available for download, details how these enhancements empower end users to maximize the impact of their data-driven research without compromising on time or budget. https://velsera.com/streamline-complex-workflows  

### 

About Velsera: 

Velsera's mission is to be the discovery, evidence generation, and clinical delivery platform for precision medicine. We help experts in clinical diagnostics and life sciences make better decisions about providing the right therapy to the right patients at the right time. Velsera was founded in 2023 by the merger of Seven Bridges, PierianDx and UgenTec and operates in the US, Europe and Asia. For more information, visit www.velsera.com. 

Media Contact 

Brian Lassiter 
Manager, Commercial Marketing 
Velsera 
Brian.lassiter@velsera.com 
(857) 357-3060 | ext 3060